MedCompanion

Brain Abscess

CNS

Source: IDMP View on spectrum chart →
Patient + scenario modifiers
Patient
Clinical scenario / source

Annotations only — chart still shows the full chemistry of each drug.

1. Clinical Syndrome

Focal pyogenic infection of brain parenchyma with central necrosis and surrounding capsule on CT/MRI (ring enhancement). Classic triad: headache, fever, focal neurologic deficit (only ~20% complete). Subacute presentation (days–weeks) vs acute fulminant in immunocompromised.

Routes of seeding define pathogen mix:

  • Contiguous (sinusitis, otitis, mastoiditis, dental) — streptococci (esp anginosus group), anaerobes, Haemophilus.
  • Hematogenous (endocarditis, lung abscess, IVDU) — S. aureus, viridans strep, GNR. Multiple lesions classic.
  • Post-traumatic / post-neurosurgical — S. aureus (MSSA/MRSA), CoNS, GNR including Pseudomonas, Cutibacterium acnes (esp shoulder + CSF shunt).
  • Immunocompromised (HIV CD4<100, transplant) — Toxoplasma, Nocardia, fungi (aspergillus, mucorales, cryptococcus), MTB; bacterial pathogens still dominate but the differential broadens.

Excludes: epidural abscess (separate workflow — usually surgical emergency), septic dural sinus thrombosis, viral encephalitis (see HSV encephalitis syndrome), tuberculous meningitis (separate ladder).

2. Pathogens

Consider the patient: Immunocompromise (HIV CD4, transplant, malignancy on chemo, prolonged steroids — broadens to Toxo, Nocardia, fungi), recent neurosurgery / head trauma, congenital cyanotic heart disease (R-to-L shunt → recurrent hematogenous abscess), structural brain lesion (prior stroke, tumor).

Consider the case: Source identifiable on imaging? Single vs multiple lesions (multi → hematogenous, immunocompromised, fungal). Severity (mass effect, herniation risk) drives urgency of surgical drainage.

Common

Less common

3. Empiric Therapy

TierFirst choiceAlternativesDurationComments
Admitted to ward
  • load + AUC-guided · — · IV · Empiric MRSA coverage
  • 2 g · q12h · IV

    **Higher meningitic dose (q12h not q24h)** to ensure CSF penetration.

  • 500 mg · q8h · IV · Empiric anaerobe coverage
  • Vanc + meropenem — · — · IV

    Substitute meropenem for CTX + metro when broader GNR / Pseudomonas coverage needed (post-neurosurgical, immunocompromised, healthcare-associated).

**6–8 weeks IV** minimum for bacterial brain abscess. Some experts step down to oral after 4–6 weeks IV if drained, susceptible organism, and bioavailable PO option.**Empiric for community-acquired brain abscess.** Vanc + CTX + metro covers most contiguous + hematogenous bacterial pathogens. **Neurosurgical drainage is essential** for any lesion >2.5 cm or causing mass effect — both diagnostic (Gram stain + culture) and therapeutic. Antibiotics alone fail for larger abscesses.
ICU — Pseudomonas risk
  • load + AUC-guided · — · IV
  • 2 g · q8h · IV

    **High-dose for CNS penetration** — meropenem preferred over imipenem in CNS due to lower seizure risk.

  • Vanc + cefepime + metro — · — · IV

    Pip-tazo NOT preferred for CNS — meropenem or cefepime have better CSF penetration.

6–8 weeks IV minimum**Post-neurosurgical / post-traumatic / immunocompromised / sepsis.** Covers MRSA + Pseudomonas + anaerobes + most GNR. Neurosurgical consult urgent.

Add coverage if:

MRSA coverage
  • Hematogenous from IVDU / endocarditis
  • Healthcare-associated
  • Post-neurosurgical
  • Prior MRSA

Add:

  • load + AUC-guided · — · IV
Pseudomonas coverage
  • Post-neurosurgical
  • Otogenic abscess (otitis externa source)
  • Immunocompromised
  • Recent broad-spectrum abx

Add:

  • 2 g · q8h · IV

    Or cefepime 2 g q8h.

Toxoplasma coverage
  • HIV with CD4 <100
  • Transplant recipient on immunosuppression
  • Multiple ring-enhancing lesions

Add:

  • 5 mg/kg TMP · q12h · IV/PO

    Preferred for empiric toxo. Pyrimethamine + sulfadiazine + leucovorin is alternative (not seeded).

4. Directed Therapy

Source control = neurosurgical drainage. Lesions >2.5 cm, mass effect, posterior fossa, or no improvement at 1–2 weeks → stereotactic aspiration or open craniotomy. Drainage provides Gram stain, culture, and decompresses.

Once organism identified, narrow:

  • MSSA: cefazolin (poor CNS penetration — use nafcillin 2 g q4h IV) or nafcillin × 6–8 weeks.
  • MRSA: vancomycin AUC-guided × 6–8 weeks. Linezolid 600 mg q12h is alternative (excellent CNS penetration).
  • Streptococcus / anginosus: PCN-G 4 MU q4h IV + metronidazole × 6–8 weeks; or ceftriaxone 2 g q12h.
  • Enterobacterales: ceftriaxone 2 g q12h IV × 6–8 weeks.
  • Pseudomonas: cefepime 2 g q8h or meropenem 2 g q8h × 6–8 weeks.
  • Anaerobes (B. fragilis): metronidazole 500 mg q8h IV; continues until drainage clear.
  • Toxoplasma: TMP-SMX or pyrimethamine + sulfadiazine + leucovorin × 6 weeks acute, then chronic suppression until ART recovery (HIV).
  • Nocardia: TMP-SMX (high dose) × 6–12 months ± imipenem or amikacin for severe / disseminated.
  • Aspergillus: voriconazole × 6–12 weeks minimum + surgical debridement; isavuconazole alternative.

Adjuncts:

  • Dexamethasone — used selectively for significant mass effect / vasogenic edema; controversial because it may impair antibiotic CNS penetration. Generally short course if needed.
  • Anticonvulsants — frequent breakthrough seizures; many start empiric anticonvulsant prophylaxis though evidence modest.

5. Monitoring

Resolution: clinical (fever, neuro deficits, mental status), serial imaging (MRI q1–2 weeks until clear stabilization, then less often). Abscess capsule eventually thins; complete radiographic resolution can take months.

Imaging: MRI with contrast is the imaging of choice (ring enhancement + DWI restricted diffusion classic). CT acceptable when MRI contraindicated.

Toxicity: vanc AUC + Cr; meropenem neurotoxicity (seizures, esp AKI); metronidazole prolonged → neuropathy (>3 weeks); LFTs.

Pearls

Drainage is essential for any lesion >2.5 cm or causing mass effect. Higher meningitic doses — ceftriaxone q12h (not q24h), meropenem 2 g q8h (not 1 g) for CNS penetration. 6–8 weeks IV minimum for bacterial; longer for fungal / mycobacterial / poorly drained. Multiple lesions in HIV with CD4 <100 = empiric toxo treatment first; SPECT-thallium or CSF EBV PCR if not improving (PCNSL on the differential). Dental + sinus + ear source dominates community-acquired; endocarditis source for hematogenous — TTE/TEE for every S. aureus / strep brain abscess.

References